Top

Published in:

01-12-2020 | Decubitus Ulcer | Case Report

Gastric AA amyloidosis secondary to chronic infection presenting with hematemesis: a case report

Authors: Yuting Huang, Salahuddin Nasir, Suryanarayana Reddy Challa, Carol Chiung-Hui Peng, Kristen Stashek, Rachel Fanaroff, Shien Hu

Published in: Clinical Journal of Gastroenterology | Issue 6/2020

Abstract

AA amyloidosis, previously known as secondary amyloidosis, has been associated with multiple chronic inflammatory conditions, including various autoimmune diseases and rarely chronic infection. Hereby, we present a case of AA amyloidosis secondary to chronic infection which initially presented with nausea and hematemesis. Endoscopic biopsies revealed diffuse AA amyloid deposition in the stomach, but not the esophagus. AA Amyloidosis presumably compromised gastric motility, promoted reflux related esophageal ulcers and erosions, and caused his cardiac and renal insufficiency. Therefore, endoscopic biopsies could be practical investigation to identify AA amyloidosis in the setting of chronic inflammatory diseases, especially with multi-organ involvement.

Available only for authorised users

Rowe K, Pankow J, Nehme F, et al. Gastrointestinal amyloidosis: review of the literature. Cureus. 2017;8(9):e1228.

Cowan AJ, Skinner M, Seldin DC, et al. Amyloidosis of the gastrointestinal tract: a 13-year, single-center, referral experience. Haematologica. 2013;98:141.PubMedPubMedCentral

Asua DR, et al. Systemic AA amyloidosis: epidemiology, diagnosis, and management. Clin Epidemiol. 2014;6:369–77.

Yen T, Chen FW, Witteles RM, et al. Clinical implications of gastrointestinal symptoms in systemic amyloidosis. Neurogastroenterol Motil. 2018;30:e13229.PubMed

Battle WM, Rubin MR, Cohen S, et al. Gastrointestinal-motility dysfunction in amyloidosis. N Engl J Med. 1979;301:24–5.PubMed

Sattianayagam PT, Hawkins PN, Gillmore JD. Systemic amyloidosis and the gastrointestinal tract. Nat Rev Gastroenterol Hepatol. 2009;6:608–17.PubMed

Lee YY, Haque MM, Lawenko RM, et al. Systemic disorders that affect gastrointestinal mobility. Clin Basic Neurogastroenterol Motility. 2020;4:601–18.

Ellen C. Ebert, michael nagar, gastrointestinal manifestations of amyloidosis. Am J Gastroenterol. 2008;103:776–87.

Sundaram S, Rathod R. Gastric amyloidosis causing nonvariceal upper gastrointestinal bleeding. ACG Case R J. 2019;6:e00066.

10.

Khan Z, Darr U, Renno A, et al. Massive upper and lower gi bleed from simultaneous primary (AL) amyloidosis of the stomach and transverse colon in a patient with multiple myeloma. Case Rep Gastroenterol. 2017;11:625–31.PubMedPubMedCentral

11.

Tada S, Iida M, Iwashita A, et al. Endoscopic and biopsy findings of the upper digestive tract in patients with amyloidosis. Gastrointest Endosc. 1990;36:10–4.PubMed

12.

HideakiKinugasa TT. Hiroyuki Okada Primary localized gastric amyloidosis mimicking a submucosal tumor-like gastrointestinal tumor. Clin Gastroenterol Hepatol. 2020;1:e4.

13.

Yanlei GL, Bundele MM, Shelat VG. Gastric outlet obstruction from gastric amyloidosis due to multiple myeloma. Clin Gastroenterol Hepatol. 2020. https://doi.org/10.1016/j.cgh.2020.04.012.CrossRefPubMed

14.

Lee YY, Haque MM, Lawenko RM, et al. Systemic disorders that affect gastrointestinal motility. Clin Basic Neurogastroenterol Motility. 2020;10:601–8.

Title: Gastric AA amyloidosis secondary to chronic infection presenting with hematemesis: a case report
Authors: Yuting Huang
Salahuddin Nasir
Suryanarayana Reddy Challa
Carol Chiung-Hui Peng
Kristen Stashek
Rachel Fanaroff
Shien Hu
Publication date: 01-12-2020
Publisher: Springer Singapore
Keywords: Decubitus Ulcer
Decubitus Ulcer
Esophagitis
Gastroesophageal Reflux Disease
Hematemesis
Esophagogastroduodenoscopy
Amyloidosis
AA Amyloidosis
Published in: Clinical Journal of Gastroenterology / Issue 6/2020
Print ISSN: 1865-7257
Electronic ISSN: 1865-7265
DOI: https://doi.org/10.1007/s12328-020-01211-7

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2020

A rare case of immunotherapy-induced cholangitis and gastritis

A rare case of plexiform neurofibroma of the liver in a patient without neurofibromatosis type 1

Advanced appendiceal goblet cell carcinoids with intestinal obstruction: two case reports

Hepatitis C virus-associated decompensated liver cirrhosis with refractory hepatic encephalopathy successfully treated by balloon-occluded retrograde transvenous obliteration after sofosbuvir/velpatasvir

A hepatic sclerosed hemangioma with drastic changes in contrast-enhanced ultrasonography

A rare case of pyogenic granuloma of the jejunum causing gastrointestinal bleeding

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials